Key takeaway: Sharda Cropchem Limited reported its Q1 FY 2026-27 financial results during the earnings call held on July 30, 2026. Management highlighted a 9% year-on-year revenue increase to Rs. 1,074 crores, with gross margins expanding by 120 basis points to 36.7%. EBITDA grew by 25% to Rs. 178 crores, reflecting improved profitability driven by a favorable product mix and growth in NAFTA and LATAM markets. However, Europe experienced a temporary decline in performance due to distributor stock cutbacks amid unusual weather conditions. Management noted that total product registrations increased to 3,016, with 1,027 applications pending approval. The company maintained its FY27 guidance of 10%-15% revenue growth and gross margins between 35%-37%. Management also confirmed a debt-free status with cash and liquid investments of Rs. 767 crores as of June 30, 2026. The call concluded with management expressing confidence in future performance despite current challenges.

Key takeaway: On July 29, 2026, Sharda Cropchem Limited submitted an investor presentation detailing its unaudited financial results for the quarter ended June 30, 2026. The presentation highlighted a total revenue of Rs. 1,074 crores, reflecting a 9% year-over-year increase, with the agrochemical segment contributing Rs. 915 crores (+8% YoY) and the non-agrochemical segment Rs. 159 crores (+15% YoY). Gross profit rose by 13% to Rs. 394 crores, and EBITDA increased by 25% to Rs. 178 crores, resulting in an EBITDA margin of 16.6%. The presentation also noted a decrease in profit after tax (PAT) by 38% to Rs. 88 crores, attributed to lower forex gains. The company emphasized its asset-light, registration-led business model and its extensive global presence across 80+ countries, supported by a network of over 525 distributors.

Key takeaway: During the earnings call for Q4 FY 2025-26, management reported that the fiscal year was the best in Sharda Cropchem's history as a listed company, achieving record PAT, EBITDA, and revenue despite global challenges. Total revenues for Q4 grew by 13% to INR 2,065 crores, with a 4% annual volume growth. The agrochemical segment contributed significantly, with a 5% volume increase. Gross margins expanded by 750 basis points to 37.3%, and EBITDA rose by 75% to INR 513 crores. Management highlighted a strong pipeline of product registrations, with 3,011 total registrations and 1,004 applications pending. For FY27, management guided toward a revenue growth of 10% to 15% and EBITDA margins of 18% to 20%. The company remains debt-free with cash and liquid investments of INR 702 crores as of March 31, 2026. A final dividend of INR 9 per share was also announced, totaling INR 15 per share for the fiscal year.

Key takeaway: The investor presentation by Sharda Cropchem Limited, dated May 13, 2026, outlines the company's audited financial results for the quarter and year ended March 31, 2026. The presentation highlights a 22% increase in total revenues to Rs. 5,268 crores, driven by a 13.3% growth in agrochemical volumes. The gross margin improved to 35.9%, and profit after tax rose significantly by 124% to Rs. 681 crores. The company reported a strong global presence, operating in over 80 countries, and emphasized its asset-light business model, which focuses on identifying generic molecules and outsourcing manufacturing. Management outlined future strategies including expanding distribution, investing in product registrations, and enhancing operational efficiencies. The presentation also noted the company's commitment to corporate social responsibility initiatives in education, healthcare, and rural development.

Key takeaway: On January 30, 2026, Sharda Cropchem Limited conducted its Q3 FY 2025-26 earnings conference call, where management reported a robust performance driven by strong volume growth and an improved product mix. The company achieved its highest-ever PAT for any year, with total revenues growing by 39% to INR 1,289 crores and a PAT of INR 145 crores, reflecting a 366% year-on-year increase. Management noted that the global agrochemical market is recovering, with inventories normalizing and demand reviving. The company has made significant progress in product registrations, with a total of 3,004 registrations and 1,076 applications in the approval stage. Gross margins expanded to 34.9%, and EBITDA grew by 59% to INR 246 crores. Management set a goal of maintaining healthy EBITDA margins in the range of 18% to 20% for FY '26. The call concluded with a Q&A session addressing various inquiries from analysts and investors.